Organon & Co. (OGN) Competitors $9.99 +0.09 (+0.86%) As of 11:46 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock OGN vs. BPMC, BBIO, VRNA, ROIV, ELAN, RVMD, LEGN, GRFS, TGTX, and LNTHShould you be buying Organon & Co. stock or one of its competitors? The main competitors of Organon & Co. include Blueprint Medicines (BPMC), BridgeBio Pharma (BBIO), Verona Pharma PLC American Depositary Share (VRNA), Roivant Sciences (ROIV), Elanco Animal Health (ELAN), Revolution Medicines (RVMD), Legend Biotech (LEGN), Grifols (GRFS), TG Therapeutics (TGTX), and Lantheus (LNTH). These companies are all part of the "pharmaceutical products" industry. Organon & Co. vs. Its Competitors Blueprint Medicines BridgeBio Pharma Verona Pharma PLC American Depositary Share Roivant Sciences Elanco Animal Health Revolution Medicines Legend Biotech Grifols TG Therapeutics Lantheus Organon & Co. (NYSE:OGN) and Blueprint Medicines (NASDAQ:BPMC) are both mid-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, analyst recommendations, media sentiment, risk, dividends, profitability and institutional ownership. Do institutionals and insiders have more ownership in OGN or BPMC? 77.4% of Organon & Co. shares are held by institutional investors. 2.0% of Organon & Co. shares are held by insiders. Comparatively, 4.2% of Blueprint Medicines shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Do analysts recommend OGN or BPMC? Organon & Co. currently has a consensus price target of $18.00, indicating a potential upside of 80.09%. Blueprint Medicines has a consensus price target of $128.25, indicating a potential downside of 0.82%. Given Organon & Co.'s stronger consensus rating and higher probable upside, equities analysts clearly believe Organon & Co. is more favorable than Blueprint Medicines.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Organon & Co. 1 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.50Blueprint Medicines 0 Sell rating(s) 17 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.24 Which has more risk and volatility, OGN or BPMC? Organon & Co. has a beta of 0.6, suggesting that its share price is 40% less volatile than the S&P 500. Comparatively, Blueprint Medicines has a beta of 0.89, suggesting that its share price is 11% less volatile than the S&P 500. Is OGN or BPMC more profitable? Organon & Co. has a net margin of 11.92% compared to Blueprint Medicines' net margin of -27.70%. Organon & Co.'s return on equity of 227.43% beat Blueprint Medicines' return on equity.Company Net Margins Return on Equity Return on Assets Organon & Co.11.92% 227.43% 7.34% Blueprint Medicines -27.70%-64.60%-17.22% Does the media refer more to OGN or BPMC? In the previous week, Organon & Co. had 47 more articles in the media than Blueprint Medicines. MarketBeat recorded 55 mentions for Organon & Co. and 8 mentions for Blueprint Medicines. Blueprint Medicines' average media sentiment score of 0.99 beat Organon & Co.'s score of 0.13 indicating that Blueprint Medicines is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Organon & Co. 4 Very Positive mention(s) 5 Positive mention(s) 40 Neutral mention(s) 3 Negative mention(s) 3 Very Negative mention(s) Neutral Blueprint Medicines 6 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has preferable earnings & valuation, OGN or BPMC? Organon & Co. has higher revenue and earnings than Blueprint Medicines. Blueprint Medicines is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOrganon & Co.$6.40B0.41$864M$2.883.47Blueprint Medicines$508.82M16.41-$67.09M-$2.47-52.35 SummaryOrganon & Co. beats Blueprint Medicines on 11 of the 16 factors compared between the two stocks. Get Organon & Co. News Delivered to You Automatically Sign up to receive the latest news and ratings for OGN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding OGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OGN vs. The Competition Export to ExcelMetricOrganon & Co.Medical Services IndustryMedical SectorNYSE ExchangeMarket Cap$2.60B$7.34B$5.59B$20.55BDividend Yield0.80%2.80%5.25%3.74%P/E Ratio3.4727.1527.5428.00Price / Sales0.4134.04415.8340.51Price / Cash2.0223.6737.0622.25Price / Book5.466.708.104.60Net Income$864M$230.16M$3.17B$982.91M7 Day Performance-0.79%2.05%3.33%0.78%1 Month Performance-0.40%2.30%3.54%4.24%1 Year Performance-49.82%43.94%33.62%14.43% Organon & Co. Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OGNOrganon & Co.4.8944 of 5 stars$10.00+0.9%$18.00+80.1%-50.0%$2.60B$6.40B3.474,000Trending NewsBPMCBlueprint Medicines1.5469 of 5 stars$128.18+0.1%$128.06-0.1%+11.5%$8.28B$562.12M-51.89640Insider TradeBBIOBridgeBio Pharma4.6926 of 5 stars$43.18-3.7%$58.85+36.3%+78.9%$8.20B$221.90M-12.23400Analyst UpgradeGap UpHigh Trading VolumeVRNAVerona Pharma PLC American Depositary Share1.7666 of 5 stars$94.58+0.8%$101.10+6.9%+514.8%$8.05B$42.28M-47.2930Trending NewsAnalyst ForecastROIVRoivant Sciences2.2616 of 5 stars$11.27-1.1%$17.50+55.3%+3.6%$7.66B$29.05M-45.08860News CoverageAnalyst ForecastELANElanco Animal Health2.3877 of 5 stars$14.29flat$15.17+6.1%+9.1%$7.10B$4.44B19.319,000RVMDRevolution Medicines4.5079 of 5 stars$36.79-0.3%$67.58+83.7%-12.3%$6.85B$11.58M-9.20250News CoveragePositive NewsLEGNLegend Biotech2.9088 of 5 stars$35.49+2.5%$76.20+114.7%-15.5%$6.52B$627.24M-60.152,609Analyst ForecastGRFSGrifols3.5204 of 5 stars$9.04+2.0%$10.30+13.9%+12.2%$6.22B$7.81B7.7323,822Analyst UpgradeGap UpTGTXTG Therapeutics3.3236 of 5 stars$35.99-2.0%$40.80+13.4%+90.5%$5.71B$386.39M149.96290Positive NewsAnalyst ForecastLNTHLantheus4.455 of 5 stars$81.86+0.5%$130.50+59.4%+7.5%$5.66B$1.53B23.26700Positive News Related Companies and Tools Related Companies BPMC Alternatives BBIO Alternatives VRNA Alternatives ROIV Alternatives ELAN Alternatives RVMD Alternatives LEGN Alternatives GRFS Alternatives TGTX Alternatives LNTH Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:OGN) was last updated on 7/10/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredHow a Kansas farm boy gained 1,285% in two daysA former farm kid placed a simple trade… and cashed out a 1,285% gain two days later. It wasn’t crypto or a...TradeSmith | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting—or plan to collect—Social Security, this could be a game-changer. A new initiative tie...InvestorPlace | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Organon & Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Organon & Co. With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
